About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

driver i hope you are right!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

I hope all three Driver, Smiler and PH!

THE MASTER

Your great source is not as clued up as he thinks he is!!!!!

Far more buys than sells yet share price down 8%+ DON'T UNERSTAND!!

Plenty of volume here the sp should be on the up.

I Know

hurry up with this news i,ve run out of finger nails

Master tell your source he needs a new crystal ball !! Driver I would just like to get to 1p at the moment but it will take a bit of positive news ! :)

smiler

:))

a little tic up this morning !! driver this could go to 5p you know !! :)

its been said these will go to 8p or more..

Genetic Technologies for Biomarker Discovery and Drug Development Boosts Demand for qRT-PCR Products

NewswireToday - /newswire/ - Palo Alto, CA, United States, 10/26/2006 - Increased emphasis on genetic technologies for biomarker discovery and drug development boosts demand for qRT-PCR products


The emerging field of differential mRNA expression analysis using qRT-PCR technologies has given new hope to the search for biomarkers and drug development efforts. The combination of fast analyses with newer multiplexing-capable qRT-PCR instruments has greatly increased the efficiency of the qRT-PCR approach, and it provides users with an invaluable source of data useful for research and clinical purposes.

New analysis from Frost and Sullivan, U.S. qRT-PCR Markets, reveals that the market earned revenues of $586.6 million in 2005 and estimates this market to reach $1229.2 million in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. qRT-PCR Markets, then send an e-mail to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.

Two factors are responsible for growth of the qRT-PCR market: newer qRT-PCR technologies provide an efficient means to simultaneously monitor expression levels of multiple genetic messages in real-time, and qRT-PCR is an extremely cost effective approach. By providing unique access to previously inaccessible information on cellular responses, qRT-PCR has revolutionized the role that genetic technologies play in the healthcare industry.

qRT-PCR technology makes it possible to spy on the internal communication between cells and their environment, states Frost & Sullivan Research Analyst Shankar Sellappan, Ph.D. The proactive approach qRT-PCR market participants have taken with respect to instrument design and reagent optimization has played a significant role in the growth of the market. As the information on how cells respond to stimuli in real-time improves the understanding of fundamental aspects of biological and disease development, strong growth of the qRT-PCR market is expected through 2012.

Given that the qRT-PCR multiplexing instrument market is relatively new, initial purchases of instruments is likely to drive demand. Furthermore, the need for robust products with enhanced capabilities is likely to offer excellent growth opportunities to smaller market participants in the fragmented qRT-PCR reagents market. For example, market participants have developed thermostable, longer-lasting qRT-PCR reagents that can withstand room temperature for as long as 24 hours, allowing full use of instruments even when laboratory personnel are not present. Manufacturers have responded to demands for lower costs by offering their products at affordable prices to cater to budget-constrained research groups.

Increased productivity of instruments that incorporate high-throughput technologies such as automated technologies to load samples, robotics to handle reagents, and pathway kits to study disease are driving demand for qRT-PCR reagents, notes Dr. Sellappan.

Adoption of qRT-PCR by additional users is likely to accelerate market growth as the technology matures. In addition to research uses, new clinical applications incorporating qRT-PCR concepts may provide distinct points in the disease cycle where therapeutic assessment and gene-based therapies, such as siRNA, can be employed.

Although growth of the qRT-PCR markets reflects improvements in capabilities, emerging microarray technologies offering a higher data per experiment ratio are compelling restraint for qRT-PCR market growth, cites Dr. Sellappan. To compete with microarray technologies, this industry must expand the number of targets capable of simultaneous analysis and must develop pathway specific products aimed at providing information on all signals in a related molecular pathway.

U.S. qRT-PCR Markets is part of the Drug Discovery Technologies subscription, which also includes research in the following markets: mass spectrometry, protein electrophoresis, DNA sequencing, RNAi, microfluidics/lab-on-a-chip, DNA microarrays, and proteomics arrays. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics

Not quite the news we are waiting for PH! sp down 0.3p at present.

Laurie. JohnB on the competitor of money am got an email from JP, the money we are about to receive is going to be more than we were all thinking

that sounded like a prayer..

amen to that ;-)

I will settle for the 9.6 million that would be a 1p maker !
Afterwards of course I,ll be greedy and look for any further scraps.

it will be a lot more than that mate ;-)

JohnDavison - 27 Oct'06 - 14:23 - 7234 of 7236


Just been reading through the posts, I'm rather surprised that people woudl think I wouldn't come back and tell you...man, some people.

As I said the other day I had been chasing up John Pool on OSI in particular trying to find out what 'Success' meant. We can all kind of guess or hope but that's not really acceptable to me. I got a few answers back but managed to get near to what I wanted as the e-mails progressed.

Not knowing anything about the the contract side of Pharma's I wanted to get clear about OSI Milestones, with that it seems the agreement will be roughly the same in most cases with the amounts per stage being the subject of variable negotiation but as the product progresses the value increases as do the payments until it is on the market, at that stage the company enjoys a percentage of sales. So if that is the case then we should see milestones at each step of the cycle.

From my point of view, for what's its worth and no advice intended, I think this means more revenue than I thought BUT I wouldn't like to even guess on numbers. Another point being that as Cannon has said before you really need to structure any question so that you don't get a bland response...I kept at John three times, trying to get more each time..and thankfully he gave me his time to answer it - thanks John.

I hope that helps and if you have any questions then I'll try to help.

BTW...this is not meant to be a Ramp, De-ramping or pump&dump, and I';m alsways true to my word.

Cheers
JD

p.s. cannon it's John D LOL

your either in or your out... ;-)

thanks for sharing the info pot head :)